Frontline Immunotherapy/Bevacizumab Ups PFS in PD-L1–Positive mRCC

March 3, 2017

This video examines a phase II study that compared atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma.

In this video, David F. McDermott, MD, of Beth Israel Deaconess Medical Center in Boston, discusses a phase II study (IMmotion 150) that compared the anti–PD-L1 agent atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma (mRCC).

With a median follow-up of 20.7 months, results of the study showed a median progression-free survival (PFS) of 14.7 months in PD-L1–positive mRCC patients who received atezolizumab/bevacizumab vs 7.8 months in patients on sunitinib alone (hazard ratio, 0.64; 95% CI, 0.38–1.08).

McDermott highlights interesting findings from the study, including patients who achieved complete responses, and notable adverse events from the combination regimen.

The study (abstract 431) was presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida.